Login / Signup

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Elodie MailleSolenn BrosseauVincent HanouxChristian CreveuilClaire DanelEmmanuel BergotArnaud ScherpereelJulien MazièresJacques MargeryLaurent GreillierClarisse Audigier-ValetteDenis Moro-SibilotOlivier MolinierRomain CorreIsabelle MonnetValérie GounantAlexandra LanglaisFranck MorinGuénaelle LevalletGérard Zalcman
Published in: British journal of cancer (2019)
MST1/hippo kinase expression loss is predictive of poor prognosis in MPM patients, leading to nuclear YAP accumulation and electing YAP as a putative target for therapeutic intervention in human MPM.
Keyphrases